NeuroOne to effect 1-for-6 reverse stock split to regain Nasdaq compliance

NEUROONE MEDICAL TECHNOLOGIES Corp

Board approved 1-for-6 reverse stock split, effective 5:00 p.m. ET on April 15, 2026.
Trading on Nasdaq will commence on split-adjusted basis under symbol NMTC on April 16, 2026.
No fractional shares; stockholders entitled to cash payment for fractional interests.
Reverse split intended to increase bid price and regain compliance with Nasdaq minimum bid rule.
Authorized shares and par value unchanged; CUSIP changes to 64130M308.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

NEUROONE MEDICAL TECHNOLOGIES Corp: Certificate of Amendment filed to effect a 1-for-6 reverse stock split of common stock (effective 2026-04-15).

Change: charter amendment
Effective: 2026-04-15

Exact text from the filing

On April 14, 2026, NeuroOne Medical Technologies Corporation (the “Company” or “NeuroOne”) filed an amendment to its Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

NEUROONE MEDICAL TECHNOLOGIES Corp filing history →

Source: SEC EDGAR

accession 0001213900-26-043239

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.